Table 2 Correlation between axillary lymph node metastasis and clinicopathological features
From: Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer
Parameters | Axillary lymph node metastasis | p value | |
|---|---|---|---|
No metastasis, including even micrometasis (n = 607) | metastasis (n = 112) | ||
Age at operation (years old) | Â | Â | 0.872 |
  ≤ 60 | 331 (54.5%) | 62 (55.4%) |  |
  > 60 | 276 (45.5%) | 50 (44.6%) |  |
Tumor size (mm) |  |  | < 0.001 |
  ≤ 10.0 | 202 (33.3%) | 15 (13.4%) |  |
  > 10.0 | 405 (66.7%) | 97 (86.6%) |  |
Estrogen receptor | Â | Â | 0.441 |
 Negative | 93 (15.3%) | 14 (12.5%) |  |
 Positive | 514 (84.7%) | 98 (87.5%) |  |
Progesterone receptor | Â | Â | 0.063 |
 Negative | 280 (46.1%) | 41 (36.6%) |  |
 Positive | 327 (53.9%) | 71 (63.4%) |  |
HER2 | Â | Â | 0.920 |
 Negative | 551 (90.8%) | 102 (91.1%) |  |
 Positive | 56 (9.2%) | 10 (8.9%) |  |
Ki67 | Â | Â | 0.734 |
  ≤ 20% | 496 (81.7%) | 90 (80.4%) |  |
  > 20% | 111 (18.3%) | 22 (19.6%) |  |
Intrinsic subtype HR + BC |  |  | 0.201 |
 No | 87 (14.3%) | 11 (9.8%) |  |
 Yes | 520 (85.7%) | 101 (90.2%) |  |
Intrinsic subtype HR-HER2 + BC |  |  | 0.911 |
 No | 584 (96.2%) | 108 (96.4%) |  |
 Yes | 23 (3.8%) | 4 (3.6%) |  |
Intrinsic subtype TNBC | Â | Â | 0.162 |
 No | 543 (89.5%) | 105 (93.8%) |  |
 Yes | 64 (10.5%) | 7 (6.3%) |  |
Lymph vascular invasion |  |  | < 0.001 |
 No | 478 (78.7%) | 50 (44.6%) |  |
 Yes | 129 (21.3%) | 62 (55.4%) |  |
Hyperlipidemia | Â | Â | 0.212 |
 No | 478 (78.7%) | 94 (83.9%) |  |
 Yes | 129 (21.3%) | 18 (16.1%) |  |
Multiple medicine types for hyperlipidemia | Â | Â | 0.460 |
 No | 601 (99.0%) | 110 (98.2%) |  |
 Yes | 6 (1.0%) | 2 (1.8%) |  |
Statins | Â | Â | 0.226 |
 Non-user | 491 (80.9%) | 96 (85.7%) |  |
 User | 116 (19.1%) | 16 (14.3%) |  |
Lipophilic statins | Â | Â | 0.042 |
 Non-user | 550 (90.6%) | 108 (96.4%) |  |
 User | 57 (9.4%) | 4 (3.6%) |  |
Hydrophilic statins | Â | Â | 0.746 |
 Non-user | 548 (90.3%) | 100 (89.3%) |  |
 User | 59 (9.7%) | 12 (10.7%) |  |
Fibrate | Â | Â | 0.624 |
 Non-user | 598 (98.5%) | 111 (99.1%) |  |
 User | 9 (1.5%) | 1 (0.9%) |  |
Nicotinic acid (tocopherol acetate) | Â | Â | 0.341 |
 Non-user | 602 (99.2%) | 110 (98.2%) |  |
 User | 5 (0.8%) | 2 (1.8%) |  |
Sterol absorption inhibitors (ezetimibe) | Â | Â | 0.941 |
 Non-user | 602 (99.2%) | 111 (99.1%) |  |
 User | 5 (0.8%) | 1 (0.9%) |  |